Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma

SIMPLE SUMMARY: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading cause of cancer-related deaths. It is difficult to treat because is it often detected at advanced stages, there are no effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Chouari, Tarak, La Costa, Francesca Soraya, Merali, Nabeel, Jessel, Maria-Danae, Sivakumar, Shivan, Annels, Nicola, Frampton, Adam E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486452/
https://www.ncbi.nlm.nih.gov/pubmed/37686543
http://dx.doi.org/10.3390/cancers15174265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486452/
https://www.ncbi.nlm.nih.gov/pubmed/37686543
http://dx.doi.org/10.3390/cancers15174265

Ejemplares similares